Use of Hemoglobin for Delivering Exogenous Carbon Monoxide in Medicinal Applications

Curr Med Chem. 2020;27(18):2949-2963. doi: 10.2174/0929867325666181113122340.

Abstract

Carbon Monoxide (CO), at low concentrations, can have a variety of positive effects on the body including anti-apoptosis, anti-inflammatory, anti-oxidative and anti-proliferative effects. Although CO has great potential for use as a potent medical bioactive gas, for it to exist in the body in stable form, it must be associated with a carrier. Hemoglobin (Hb) represents a promising material for use as a CO carrier because most of the total CO in the body is stored associated with Hb in red blood cells (RBC). Attempts have been made to develop an Hb-based CO carrying system using RBC and Hb-based artificial oxygen carriers. Some of these have been reported to be safe and to have therapeutic value as a CO donor in preclinical and clinical studies. In the present review, we overview the potential of RBC and Hb-based artificial oxygen carriers as CO carriers based on the currently available literature evidence for their use in pharmaceutical therapy against intractable disorders.

Keywords: Hemoglobin; anti-apoptosis; anti-proliferative effects; carbon monoxide; hemoglobin-based oxygen carriers; red blood cell..

Publication types

  • Review

MeSH terms

  • Carbon Monoxide
  • Erythrocytes
  • Hemoglobins / metabolism*
  • Oxygen
  • Pharmaceutical Preparations

Substances

  • Hemoglobins
  • Pharmaceutical Preparations
  • Carbon Monoxide
  • Oxygen